Residential College | false |
Status | 已發表Published |
Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions | |
Liu, Chunping1,2,3,4; Chen, Huiqi1; Guo, Sien1; Liu, Qiaojing1; Chen, Zhijun1; Huang, Haiding1; Zhao, Qi5; Li, Longmei1; Cen, Huan1; Jiang, Zebo6; Luo, Qiyuan7; Chen, Xiaoling8; Zhao, Jiaxiong1; Chen, Wensheng2; Yang, Phillip C.9; Wang, Lei1,2 | |
2023-10-01 | |
Source Publication | Biomedicine and Pharmacotherapy |
ISSN | 0753-3322 |
Volume | 166 |
Abstract | With the progression of tumor treatment, the 5-year survival rate of breast cancer is close to 90%. Cardiovascular toxicity caused by chemotherapy has become a vital factor affecting the survival of patients with breast cancer. Anthracyclines, such as doxorubicin, are still some of the most effective chemotherapeutic agents, but their resulting cardiotoxicity is generally considered to be progressive and irreversible. In addition to anthracyclines, platinum- and alkyl-based antitumor drugs also demonstrate certain cardiotoxic effects. Targeted drugs have always been considered a relatively safe option. However, in recent years, some random clinical trials have observed the occurrence of subclinical cardiotoxicity in targeted antitumor drug users, which may be related to the effects of targeted drugs on the angiotensin converting enzyme, angiotensin receptor and β receptor. The use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and beta-blockers may prevent clinical cardiotoxicity. This article reviews the toxicity and mechanisms of current clinical anti-breast cancer drugs and proposes strategies for preventing cardiovascular toxicity to provide recommendations for the clinical prevention and treatment of chemotherapy-related cardiomyopathy. |
Keyword | Anthracycline Breast cancer Cardiomyopathy Cardiotoxicity Chemotherapy Trastuzumab |
DOI | 10.1016/j.biopha.2023.115373 |
URL | View the original |
Language | 英語English |
Scopus ID | 2-s2.0-85169028123 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | University of Macau |
Affiliation | 1.State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China 2.Department of Cardiovascular Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China 3.Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou, Guangdong Province, 510080, China 4.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China 5.School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, Guangdong Province, 529020, China 6.Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, China 7.Health Science Center, Shenzhen University, Shenzhen, Guangdong Province, 518060, China 8.Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China 9.Cardiovascular Stem Cell (Yang) Laboratory, Stanford University School of Medicine, Stanford, 94305, United States |
First Author Affilication | Institute of Chinese Medical Sciences |
Recommended Citation GB/T 7714 | Liu, Chunping,Chen, Huiqi,Guo, Sien,et al. Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions[J]. Biomedicine and Pharmacotherapy, 2023, 166. |
APA | Liu, Chunping., Chen, Huiqi., Guo, Sien., Liu, Qiaojing., Chen, Zhijun., Huang, Haiding., Zhao, Qi., Li, Longmei., Cen, Huan., Jiang, Zebo., Luo, Qiyuan., Chen, Xiaoling., Zhao, Jiaxiong., Chen, Wensheng., Yang, Phillip C.., & Wang, Lei (2023). Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions. Biomedicine and Pharmacotherapy, 166. |
MLA | Liu, Chunping,et al."Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions".Biomedicine and Pharmacotherapy 166(2023). |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment